AAIC 2025 Abstract
Baseline characteristics from CELIA: A Phase 2 study to evaluate BIIB080 in participants with Early Alzheimer’s Disease
Trial in peopleInterventions
Abstract
Background: While the recent availability of amyloid‐targeting disease‐modifying therapies marks a major therapeutic advancement, significant unmet need remains for treatment of Alzheimer’s disease (AD).
